Join us in-person in New York City, USA for the Interphex 2026 event. Learn more about our involvement in the event below.
Just - Evotec Biologics at Interphex 2026
Presentation
Economical, Faster, Flexible: A Blueprint for Biopharmaceutical Capacity
Date and time: Thursday April 23, 2026, 10:30 AM – 11:15 AM
Location: Contract & Outsourcing Exchange Stage
Speakers:
- Lisa Connell-Crowley, SVP Process & Product Design, Just - Evotec Biologics
- Michael Holligan, Director, Capital Projects, Just - Evotec Biologics
The interest in building U.S. manufacturing capacity continues to be driven by the pace of biologics innovation. Current solutions include fitting a new product in a multi-product facility by modifying internal infrastructure and balancing constrained capacity, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs”), or investing additional capital expenditure for new sites. At Just - Evotec Biologics we have developed a reproducible facility template (J.POD®) with continuous and hybrid manufacturing trains, known as J.Train™, to enable sponsors to expand capacity rapidly and cost effectively. The presentation will share details of the template and how industry can adopt to support the challenges found in today's global drug substance needs.
Included in the presentation will be timelines and shared learnings in the manufacturing facility design, installation, integration approach and automation (digital technology) supporting the continuous manufacturing platform technology. Highlights of installation, qualification and running modular clean rooms, single-use systems, and automation to enable continuous upstream and downstream processing of drug substance will be shared along with lessons learned. Learn how to rapidly integrate small footprint end-to-end fully continuous manufacturing capabilities and processes into existing facilities to support capacity expansion needs or, invest in understanding the elements of a stand- alone J.POD® facility; can be built in less than 18 months rapidly expanding commercial-scale manufacturing capacity, especially when compared with typical large-scale fed-batch expansion efforts.
